Araki Kana, Masaki Takayuki, Katsuragi Isao, Kakuma Tetsuya, Yoshimatsu Hironobu
Department of Internal Medicine 1, Faculty of Medicine, Oita University, Oita, Japan.
Obesity (Silver Spring). 2008 Sep;16(9):2068-73. doi: 10.1038/oby.2008.323.
The aim of this study was to investigate the in vivo effects of pravastatin on the development of obesity and diabetes in diet-induced obese (DIO) mice.
We examined food intake, body-weight changes, visceral white adipose tissue (WAT) adiponectin and resistin levels, and energy metabolism.
Treatment with 100 mg/kg/day pravastatin for 28 days decreased diet-induced weight gain and visceral adiposity. In addition, the weight of the WAT, the triglyceride (TG) contents of the liver and muscles, and the levels of serum insulin improved in the pravastatin-treated DIO mice. Furthermore, pravastatin treatment changed the WAT adiponectin and resistin mRNA expression and serum levels compared with the controls. Finally, pravastatin treatment increased oxygen consumption and decreased the respiratory quotient (RQ).
Pravastatin treatment prevents the development of obesity and diabetes in DIO mice. The prevention of obesity may be mediated by increased oxygen consumption and a decrease in the RQ. These results provide novel insights into the use of pravastatin as a therapeutic tool for metabolic syndromes.
本研究旨在探讨普伐他汀对饮食诱导肥胖（DIO）小鼠肥胖和糖尿病发生发展的体内作用。
我们检测了食物摄入量、体重变化、内脏白色脂肪组织（WAT）脂联素和抵抗素水平以及能量代谢。
以100 mg/kg/天的剂量给予普伐他汀治疗28天可减少饮食诱导的体重增加和内脏脂肪堆积。此外，在接受普伐他汀治疗的DIO小鼠中，WAT的重量、肝脏和肌肉中的甘油三酯（TG）含量以及血清胰岛素水平均有所改善。此外，与对照组相比，普伐他汀治疗改变了WAT脂联素和抵抗素的mRNA表达及血清水平。最后，普伐他汀治疗增加了耗氧量并降低了呼吸商（RQ）。
普伐他汀治疗可预防DIO小鼠肥胖和糖尿病的发生发展。肥胖的预防可能是通过增加耗氧量和降低RQ来介导的。这些结果为普伐他汀作为代谢综合征治疗工具的应用提供了新的见解。
